

Author Index Volume 19 (2007)

The issue number is given in front of the page numbers.

- Alj, L., M.D.W. Touzani, R. Benkirane, I.R. Edwards and R. Soulaymani, Detecting medication errors in pharmacovigilance database: Capacities and limits (4) 187–194
- Barnes, J.C., Pharmacovigilance: Learnings from pergolide (3) 169–170
- Benkirane, R., see Alj, L. (4) 187–194
- Breggin, G., see Breggin, P.R. (4) 203–207
- Breggin, P.R., Intoxication anosognosia: The spellbinding effect of psychiatric drugs (1,2) 3–15
- Breggin, P.R. and G. Breggin, Exposure to SSRI antidepressants *in utero* causes birth defects, neonatal withdrawal symptoms and brain damage (4) 203–207
- Chatterjee, S., A. Ghosh, J. Pal and A. Mandal, Serious adverse drug reactions in a case of neurotuberculosis (3) 175–178
- Chopra, D., see Rehan, H.S. (4) 223–227
- Chundru, S.D., see Khan, S.A. (4) 179–185
- Croft, A.M., Developing safe antimalaria drugs: Key lessons from mefloquine and halofantrine (3) 153–161
- Curameng, J.M.B., see Hartigan-Go, K.Y. (1,2) 93–97
- Dukes, M.N.G. and E. 't Hoen, Compensation for drug injury: A novel solution for diethylstilbestrol? (1,2) 87–91
- Edwards, I.R., see Alj, L. (4) 187–194
- Ejaj, A., see Joshi, M.C. (4) 195–201
- Ellul, A., see Savona-Ventura, C. (4) 229–236
- Gatt, M., see Savona-Ventura, C. (4) 229–236
- Ghosh, A., see Chatterjee, S. (3) 175–178
- Grima, S., see Savona-Ventura, C. (4) 229–236
- Hartigan-Go, K.Y. and J.M.B. Curameng, The doctor as expert witness in court: Observations and lessons from the Philippines (1,2) 93–97
- Healy, D., A. Herxheimer and D.B. Menkes, Antidepressants and violence: Problems at the interface of medicine and law (1,2) 17–33
- Healy, D. and J. Le Noury, Pediatric bipolar disorder: An object of study in the creation of an illness (4) 209–221
- Herxheimer, A., British diplomat cleared of drunk flying charges: Paroxetine was involved (1,2) 35–40
- Herxheimer, A., see Healy, D. (1,2) 17–33
- Hugman, B., Tort, error and talk: What can we learn from the litigation crisis? (1,2) 75–86
- Jaquenoud Sirot, E., see van der Velden, J.W. (3) 145–151

- Jimmy, B., J. Jose and P.G.M. Rao, Drug interaction related information sought from a hospital based drug information center (3) 127–133
- Jimmy, B., see Jose, J. (3) 167–168
- Jose, J., P.G.M. Rao and B. Jimmy, Adverse drug reactions as a potential contributing factor for inadequate anti-infective drug therapy (3) 167–168
- Jose, J., see Jimmy, B. (3) 127–133
- Joshi, H.S., see Joshi, M.C. (4) 195–201
- Joshi, M.C., H.S. Joshi, K. Tariq, A. Ejaj, S. Prayag and A. Raju, A prospective study of medication errors arising out of look-alike and sound-alike brand names confusion (4) 195–201
- Kakkar, A.K., see Rehan, H.S. (4) 223–227
- Kansakar, P.S., see Khan, S.A. (4) 179–185
- Kapp, M.B., The business case for medical informed consent (1,2) 57– 64
- Kapur, V., see Mandavi (3) 111–116
- Kean, B., Claim and counterclaim: The treatment of Attention Deficit Hyperactivity Disorder (ADHD) – Preventing or contributing to the development of Substance Use Disorder (SUD)? (1,2) 65– 74
- Khan, S.A., S.D. Chundru, G.S. Rodrigues, N. Pokharel and P.S. Kansakar, From mono, multiple to extensive drug resistant TB: Where are we heading for? (4) 179–185
- Le Noury, J., see Healy, D. (4) 209–221
- Mandal, A., see Chatterjee, S. (3) 175–178
- Mandavi, P. Tiwari and V. Kapur, Inappropriate drug prescribing identified among Indian elderly hospitalized patients (3) 111–116
- Menkes, D.B., see Healy, D. (1,2) 17– 33
- Pal, J., see Chatterjee, S. (3) 175–178
- Pokharel, N., see Khan, S.A. (4) 179–185
- Prayag, S., see Joshi, M.C. (4) 195–201
- Raju, A., see Joshi, M.C. (4) 195–201
- Rao, P.G.M., see Jimmy, B. (3) 127–133
- Rao, P.G.M., see Jose, J. (3) 167–168
- Rastogi, R., see Rastogi, S. (3) 117–125
- Rastogi, S., R. Rastogi and R.H. Singh, Adverse effects of Ayurvedic drugs: An overview of causes and possibilities in reference to a case of Vatsanabha (Aconite) overdosing (3) 117–125
- Rehan, H.S., D. Chopra and A.K. Kakkar, Causality assessment of spontaneously reported adverse drug events: Comparison of WHO-UMC criteria and Naranjo probability scale (4) 223–227
- Ritlewski, K.M., Conflicts of interest in medical research in Germany and USA: A scrutiny of legal and ethical guidelines for reviewers and investigators (1,2) 41– 56
- Rodrigues, G.S., see Khan, S.A. (4) 179–185
- Savona-Ventura, C., K. Zammit, S. Grima, A. Ellul and M. Gatt, Diabetes in pregnancy: A clinical audit of cases delivered in the Maltese Islands during 1999–2004 (4) 229–236
- Singh, R.H., see Rastogi, S. (3) 117–125
- Soulaymani, R., see Alj, L. (4) 187–194
- Tariq, K., see Joshi, M.C. (4) 195–201
- 't Hoen, E., see Dukes, M.N.G. (1,2) 87– 91
- Tiwari, P., see Mandavi (3) 111–116
- Touzani, M.D.W., see Alj, L. (4) 187–194

- van Boxtel, C.J., “If nothing goes wrong, is everything alright?” in reverse (1,2) 99–103
- van der Velden, J.W and E. Jaquenoud Sirot, Effective risk management tools (3) 145–151
- Wollersheim, H., Clinical incidents and risk prevention (3) 135–143
- Zammit, K., see Savona-Ventura, C. (4) 229–236